Lexicon Pharmaceuticals Releases Positive Clinical Trial Results and Facebook Plans Mobile Payment Services
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. The trial achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control.
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.
Get more information on Lexicon Pharmaceuticals, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/LXRX
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Facebook, Inc. (NASDAQ: FB) is planning on releasing a mobile payment service according to the Financial Times who cited several people involved in the process. Facebook is close to obtaining approval from the Central Bank of Ireland to start a service that would allow users to store money on Facebook and use it to pay and exchange with others, according to the sources. Both Facebook and the Irish central bank declined to comment.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications. The company’s products include Facebook mobile app and Website that enable people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Messenger, a mobile-to-mobile messaging application available on iOS and Android phones; and Instagram, a mobile app and Website that enable people to take photos or videos, customize them with filter effects, and share them with friends and followers in a photo feed or send them directly to friends.
Get more information on Facebook, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/FB
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Tags: